{"DataElement":{"publicId":"2725450","version":"1","preferredName":"Qualitative Evaluation Anatomic Site Negative F-18 16 Alpha-Fluoroestradiol Count","preferredDefinition":"Numeric value to indicate the number of Fluoroestradiol (FES) qualitatively negative anatomic sites identified through an imaging evaluation. [Manually-curated]","longName":"QUAL_STE_NEG_FES_CT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2725446","version":"1","preferredName":"Qualitative Evaluation Anatomic Site Negative F-18 16 Alpha-Fluoroestradiol","preferredDefinition":"A type of evaluation that is primarily descriptive and interpretative, and may or may not lend itself to quantification. Mainly concerned with the properties, the state, and the character (i.e., the nature) of phenomena. It implies an emphasis on processes and meanings that are rigorously examined, but not measured in terms of quantity, amount, or frequency. (www.unfpa.org/monitoring/toolkit/glossary.pdf and Nonprofit Good Practice Guide Glossary)_Named locations of, or within, the body._Negative; not indicating the presence of microorganisms or disease or a specific condition._A radiopharmaceutical containing an estradiol analog radiolabeled with fluorine F 18, a positron emitting isotope, used as a tracer in positron emission tomography (PET). F-18 16 alpha-fluoroestradiol is actively taken up in tumor cells expressing the estrogen receptor (ER), thereby allowing visualization of ER-positive cells upon PET. The uptake of F-18 16 alpha-fluoroestradiol is dependent upon changes in ER levels in the target tissue.","longName":"QUAL_ANAT_NEG_FES","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2725443","version":"1","preferredName":"Qualitative Evaluation Anatomic Site","preferredDefinition":"A type of evaluation that is primarily descriptive and interpretative, and may or may not lend itself to quantification. Mainly concerned with the properties, the state, and the character (i.e., the nature) of phenomena. It implies an emphasis on processes and meanings that are rigorously examined, but not measured in terms of quantity, amount, or frequency. (www.unfpa.org/monitoring/toolkit/glossary.pdf and Nonprofit Good Practice Guide Glossary):Named locations of, or within, the body.","longName":"C49143:C13717","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Qualitative Evaluation","conceptCode":"C49143","definition":"A type of evaluation that is primarily descriptive and interpretative, and may or may not lend itself to quantification. Mainly concerned with the properties, the state, and the character (i.e., the nature) of phenomena. It implies an emphasis on processes and meanings that are rigorously examined, but not measured in terms of quantity, amount, or frequency. (www.unfpa.org/monitoring/toolkit/glossary.pdf and Nonprofit Good Practice Guide Glossary)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anatomic Site","conceptCode":"C13717","definition":"Named locations of or within the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44F05316-82B3-3A94-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-30","modifiedBy":"ONEDATA","dateModified":"2008-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2725444","version":"1","preferredName":"Negative F-18 16 Alpha-Fluoroestradiol","preferredDefinition":"Negative; not indicating the presence of microorganisms or disease or a specific condition.:A radiopharmaceutical containing an estradiol analog radiolabeled with fluorine F 18, a positron emitting isotope, used as a tracer in positron emission tomography (PET). F-18 16 alpha-fluoroestradiol is actively taken up in tumor cells expressing the estrogen receptor (ER), thereby allowing visualization of ER-positive cells upon PET. The uptake of F-18 16 alpha-fluoroestradiol is dependent upon changes in ER levels in the target tissue.","longName":"C38757:C62541","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negative Finding","conceptCode":"C38757","definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"F-18 16 Alpha-Fluoroestradiol","conceptCode":"C62541","definition":"A radiopharmaceutical consisting of an estradiol analogue radiolabeled with the positron-emitting isotope fluorine F 18. F-18 16 alpha-fluoroestradiol is actively taken up in tumor cells expressing the estrogen receptor (ER), allowing visualization of ER-positive tumor cells with positron emission tomography (PET). Uptake of this agent depends upon the ER status of target tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44F05316-82C4-3A94-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-30","modifiedBy":"ONEDATA","dateModified":"2008-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2233241","version":"1","preferredName":"Medical Imaging","preferredDefinition":"Events, people, materials and activities uniquely defined by medical imaging.  ","longName":"MEDICAL IMAGING","context":"CIP","contextVersion":"2.31","origin":"DICOM:Digital Imaging and Communications in Medicine","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96173D7-A9B4-3CBB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44F05316-82D5-3A94-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2018392","version":"1","preferredName":"Count","preferredDefinition":"The quantity of the specified item.","longName":"CT","context":"NCI Standards","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261845","version":"1","preferredName":"Count","preferredDefinition":"To determine the number or amount of something; the result of this activity.","longName":"C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-646B-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-13","modifiedBy":"ONEDATA","dateModified":"2005-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B3BF4389-4489-5F2C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-09","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-01-08","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/11/17 tt transferred context, added reg status and CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2812731","version":"1","longName":"U Washington","context":"NCIP"},{"publicId":"2812732","version":"1","longName":"FES Study","context":"NCIP"},{"publicId":"2812734","version":"1","longName":"U Washington New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"# FES Negative Sites","type":"Preferred Question Text","description":"# FES Negative Sites","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"44EF9532-AF5B-46A3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-01-30","modifiedBy":"REEVESD","dateModified":"2011-03-18","changeDescription":"Curated to support U Washington adoption of C3D for FES trial.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}